<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A randomized clinical trial designed to compare the effectiveness of cytoxan (<z:chebi fb="3" ids="3498">CTX</z:chebi>) alone versus a combination consisting of <z:chebi fb="3" ids="3498">CTX</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi> (Oncovin) and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (COM) in the treatment of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) was carried out </plain></SENT>
<SENT sid="1" pm="."><plain>Nineteen patients were selected at random to receive <z:chebi fb="3" ids="3498">CTX</z:chebi> alone while 21 received COM </plain></SENT>
<SENT sid="2" pm="."><plain>The two treatment regimens were equally effective in inducing remissions, and complete response rates of 83.3% and 84.3% were observed for <z:chebi fb="3" ids="3498">CTX</z:chebi>- and COM-treated patients, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>The relapse frequencies were also equal but the pattern of relapse was clearly different </plain></SENT>
<SENT sid="4" pm="."><plain>Seven out of 8 (87.5%) in the <z:chebi fb="3" ids="3498">CTX</z:chebi> group relapsed with systemic and central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, while 8 out of 10 (80%) in the COM group relapsed with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease only </plain></SENT>
<SENT sid="5" pm="."><plain>This difference is highly significant p = 0.008 </plain></SENT>
<SENT sid="6" pm="."><plain>The remission durations and survival to date are the same </plain></SENT>
</text></document>